drugset / Trial / NCT06013995

A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

NCT06013995 ↗

Phase 1 Completed 45 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate safety, drug levels and drug effects on cells and organs of the body, after receiving multiple increasing doses of BMS-986326 via intravenous (IV) infusion or subcutaneous (SC) injection, in participants with different forms of lupus.

Timeline

Start
2023-09-21
Primary completion
2026-04-14
Completion
2026-04-14

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986326 Unknown — Intravenous

Indications